Leal Therapeutics Announces $30 Million Series A to Progress First-In-Class Neuro-Metabolic Therapies for Neurodegenerative and Neuropsychiatric Disorders with High-Unmet Need August 27, 2025
Leal Therapeutics Announces $45 Million Financing to Progress Novel Therapies for Patients with Major Neurodegenerative and Neuropsychiatric Disorders October 30, 2024
Endpoints NewsExclusive: Neuro startup Leal raises $30M Series A for schizophrenia and ALS trials August 26, 2025
Endpoints NewsExclusive: Top neuroscientist Asa Abeliovich targets ALS, schizophrenia with new startup Leal after $1B Lilly buyout February 7, 2024
Endpoints NewsScoop: Star neuroscientist Asa Abeliovich and OrbiMed are teaming on yet another biotech February 14, 2022
